Article
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.
Cancer prevention research (Philadelphia, Pa.) - 1 Jun 2011
Dragnev Konstantin H, Ma Tian, Cyrus Jobin, Galimberti Fabrizio, Memoli Vincent, Busch Alexander M, Tsongalis Gregory J, Seltzer Marc, Johnstone David, Erkmen Cherie P, Nugent William, Rigas James R, Liu Xi, Freemantle Sarah J, Kurie Jonathan M, Waxman Samuel, Dmitrovsky Ethan
Abstract excerpt
The rexinoid bexarotene represses cyclin D1 by causing its proteasomal degradation. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib represses cyclin D1 via different mechanisms. We conducted a preclinical study and 2 clinical/translational trials (a window-of-opportunity and phase II) of bexarotene plus erlotinib. The combination repressed growth and cyclin D1 expression in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.